Compare Incyte Corporation (INCY) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Ulta Beauty Inc — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while Ulta Beauty Inc trades at $489.47 (market cap $20.98B). The key difference: Incyte Corporation and Ulta Beauty Inc are close in size by market cap, and Incyte Corporation is trading nearer its 52-week high, Ulta Beauty Inc nearer its low. Which is the better fit depends on your goals.
| INCY | ULTA | |
|---|---|---|
Market Cap | $23.11B | $20.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $706.82 |
52-Week Low | $67.38 | $450.75 |
Enterprise Value | $19.13B | $23.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
ULTA Beauty trades at $489.47, up 2.06% with a bullish technical signal despite mixed moving averages. The company maintains strong profitability with 39.33% gross margins and 47.45% ROE, though net margins have declined from 12.17% in 2023 to 10.63% in 2025. Recent Q1 2026 earnings beat expectations at $7.74 EPS versus $6.89 expected, while Q4 2025 missed. Analyst consensus remains strongly positive with 26 buy ratings and a $618.29 price target, representing 26% upside potential.
ULTA presents a compelling growth story with international expansion and digital engagement driving long-term potential. However, investors face risks from margin compression, competitive pressures in beauty retail, and volatile cash flow patterns. The stock's current valuation at 18.29x P/E appears reasonable given growth prospects, but requires monitoring of consumer spending trends and execution on strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
